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Background: Tumour cells rely on glycolysis and mitochondrial oxidative phosphorylation (OXPHOS) to survive.
Thus, mitochondrial OXPHOS has become an increasingly attractive area for therapeutic exploitation in cancer.
However, mitochondria are required for intracellular oxygenation and normal physiological processes, and it
remains unclear which mitochondrial molecular mechanisms might provide therapeutic benefit. Previously, we
discovered that coiled-coil-helix-coiled-coil-helix domain-containing protein 4 (CHCHD4) is critical for regulating
intracellular oxygenation and required for the cellular response to hypoxia (low oxygenation) in tumour cells
through molecular mechanisms that we do not yet fully understand. Overexpression of CHCHD4 in human cancers
correlates with increased tumour progression and poor patient survival.
Results: Here, we show that elevated CHCHD4 expression provides a proliferative and metabolic advantage to
tumour cells in normoxia and hypoxia. Using stable isotope labelling with amino acids in cell culture (SILAC) and
analysis of the whole mitochondrial proteome, we show that CHCHD4 dynamically affects the expression of a
broad range of mitochondrial respiratory chain subunits from complex I–V, including multiple subunits of complex
I (CI) required for complex assembly that are essential for cell survival. We found that loss of CHCHD4 protects
tumour cells from respiratory chain inhibition at CI, while elevated CHCHD4 expression in tumour cells leads to
significantly increased sensitivity to CI inhibition, in part through the production of mitochondrial reactive oxygen
species (ROS).
Conclusions: Our study highlights an important role for CHCHD4 in regulating tumour cell metabolism and reveals
that CHCHD4 confers metabolic vulnerabilities to tumour cells through its control of the mitochondrial respiratory
chain and CI biology.
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Metabolic reprogramming and altered mitochondrial
metabolism is a feature of cancer and thus has become
an attractive area for therapeutic exploitation [1, 2].
Given the importance of mitochondria in controlling
normal physiological processes, understanding how
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cancer.
Previously, we discovered the essential redox-sensitive
mitochondrial intermembrane space (IMS) protein
CHCHD4 is critical for regulating basal oxygen con-
sumption rate (OCR) and metabolic responses to low
oxygen (hypoxia) in tumour cells [3, 4]. Overexpression
of CHCHD4 in human cancers significantly correlates
with the hypoxia gene signature, tumour progression,
disease recurrence and poor patient survival [3].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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mediated protein folding function along with the sulfhy-
dryl oxidase GFER (ALR/Erv1) as a key part of the disul-
fide relay system (DRS) within the mitochondrial IMS
[5–7]. As such, CHCHD4 controls the import of a num-
ber of mitochondrial proteins that contain a twin-CX9C
or twin-CX3C motif [8–10]. Additionally, as a compo-
nent of the DRS, CHCHD4 participates in electron
transfer to complex IV (CIV), the molecular oxygen ac-
ceptor of the respiratory chain [11]. We and others have
found that the functionally conserved cysteines within
the redox-sensitive Cys-Pro-Cys (CPC) domain of
CHCHD4 regulate its mitochondrial localisation in yeast
[12–14] and human cells [3, 15]. Recently, we discovered
that CHCHD4 regulates intracellular oxygenation in
tumour cells, which is dependent on the functionally im-
portant cysteines of the CPC motif and CIV activity [4].
In this study, using both loss- and gain-of-function ap-
proaches, we have further explored the mitochondrial
mechanism(s) by which CHCHD4 regulates respiratory
chain function and tumour cell metabolism.
Methods
Cell culture and cell line generation
Human osteosarcoma U2OS control and independent
clonal cell lines (WT.cl1 and WT.cl3) expressing
CHCHD4.1 cDNA (CHCHD4-WT-expressing cells) or
CHCHD4-C66A/C668A cDNA (CHCHD4-(C66A/C68A)-
expressing cells) have been described by us recently [4].
Human U2OS-HRE-luc [16] or human HCT116 colon car-
cinoma cells [17] were used to stably express two independ-
ent shRNA control vectors (empty vector (shRNA control
1) and GFP vector (shRNA control 2)) or two independent
shRNAs targeting CHCHD4 (CHCHD4 shRNA1 or
CHCHD4 shRNA2) utilising a green fluorescent protein
(GFP)-SMARTvector™ pre-packaged lentivirus system from
ThermoFisher Scientific. Independent cell lines were se-
lected, expanded and characterised. All cell lines were
maintained in Dulbecco’s modified Eagle medium (DMEM)
containing 4.5 g/L glucose (#41966-029, Life Technologies)
and supplemented with 10% fetal calf serum (#EU-000-F,
SeraLabs), 100 IU/mL penicillin/100 μg/mL streptomycin
(#15140-122, Life Technologies) and 6mML-glutamine
(#25030-024, Life Technologies). Cell lines used were au-
thenticated and routinely confirmed to be negative for any
mycoplasma contamination. Hypoxia was achieved by incu-
bating cells in 1% O2, 5% CO2 and 94% N2 in a Ruskinn
SCI-tive workstation, without agitation.
Antibodies and reagents
For antibodies, the catalogue number and working dilu-
tion used are indicated in brackets. The rabbit polyclonal
CHCHD4 (HPA34688, 1:1000) antibody was purchased
from Cambridge Biosciences. The mouse monoclonalHIF-1α antibody (#610959, 1:500) was purchased from
BD Biosciences. The mouse monoclonal β-actin (ab6276,
1:10000), mouse monoclonal α-Tubulin (ab7291,
1:1000), rabbit polyclonal NDUFS3 (ab110246, 1:500)
and rabbit polyclonal UQCRC2 (ab14745, 1:1000) were
purchased from Abcam. The mouse monoclonal
anti-myc (9B11 clone, #2276, 1:1000)), rabbit polyclonal
PHB1 (#2426, 1:1000), rabbit polyclonal HIF-2α (#7096,
1:1000), rabbit polyclonal AIF (#4642, 1:1000), rabbit
polyclonal SDHA (#11998, 1:1000) and rabbit monoclonal
COXIV (3E11 clone, #4850, 11000) antibodies were pur-
chased from Cell Signaling Technology. The donkey
anti-rabbit (NA934, 1:1000) and anti-mouse (NA931,
1:1000) horseradish peroxidase (HRP)-linked secondary
antibodies were purchased from VWR. The GFER rabbit
polyclonal antibody (#HPA041227, 1:1000), oligomycin
(#75351), rotenone (#R8875), FCCP (#C2920), TMRM
(#T5428), D-glucose (#G8270), 2-deoxy-D-glucose (#D8375)
and sodium azide (NaAzide, #S8032) were purchased from
Sigma-Aldrich. MitoSOX Red (#M36008) was purchased
from ThermoFisher Scientific. MitoView Green (#70054)
was purchased from Biotium. 2-NBDG (#N13195) was pur-
chased from Life Technologies. Trolox (#648471) was pur-
chased from Merck Millipore. BAY 87-2243 (#HY-15836)
was purchased from MedChemTronica AB. NSC-134754,
3-ethyl-9,10-dimethoxy-2-(1,2,3,4-tetrahydro-isoquinoli-
n-1-ylmethyl)- 1,6,7,11b-tetrahydro-4H-pyrido[2,1-a]isoqui-
noline was obtained from the National Cancer Centre,
Drug Therapeutic Program (NCI-DTP), Frederick, MD,
and dissolved in dimethyl sulfoxide (DMSO) as we have de-
scribed previously [16, 18–20].
Gene silencing
Non-silencing siRNA duplexes (MISSION® siRNA Uni-
versal Negative Control #1, SIC-001) and custom-
designed siRNA duplexes were purchased from
Sigma-Aldrich and transfected into subconfluent cells
using HiPerfect transfection (QIAGEN) according to the
manufacturer’s instructions. The target sequences for
CHCHD4 were 5′-GAGGAAACGTTGTGAATTA-3′
(siRNA1) and 5′-AAGATTTGGACCCTTCCATTC-3′
(siRNA2). The target sequences for HIF1A were 5′-TACG
TTGTGAGTGGTATTATT-3′ (siRNA1) and 5′-TAGA
AGGTATGTGGCATTTAT-3′ (siRNA2)(Additional file1).
For the generation of stable shRNA expressing cells, ad-
herent HCT116 or U2OS-HRE-luc cells were incubated
in DMEM containing 50mg/mL Hexadimethrine bromide
(polybrene, #H9268, Sigma-Aldrich). Immediately fol-
lowing addition of polybrene-containing DMEM, len-
tiviral particles were added containing either a
non-shRNA control vector (shRNA control 1), a
non-shRNA GFP control vector (shRNA control 2) or
vectors expressing CHCHD4-targeted shRNA se-
quences (CHCHD4 shRNA1, CHCHD4 shRNA2). All
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moFisher Scientific) and target sequences are detailed
in Additional file 1. After 72 h of incubation with len-
tiviral particles, media were replaced with mainten-
ance DMEM (w/o polybrene/lentivirus), and were
cells incubated for a further 72 h. Selection of transduced
cell pools carried out by the addition of 0.5 μg/mL puro-
mycin (#P9620, Sigma-Aldrich) to the culture medium,
followed by incubation for > 96 h. Knockdown confirmed
by both western blotting for CHCHD4 protein expression
and Q-PCR for CHCHD4 transcript expression.
Gene expression analysis
Total RNA samples were isolated using the GeneElute
kit (#RTN350), following the manufacturer’s protocol
(Sigma-Aldrich). cDNA synthesis was carried out using
the qScript synthesis kit (#95048-100), following the
manufacturer’s protocol (Quantabio). mRNA expression
was measured by quantitative (Q)-PCR using SYBR
Green Mastermix (#RT-SY2X-NRWOU+B, Eurogentec
Ltd.) and the DNA Engine Opticon 2 system (BioRad).
The Q-PCR primer sequences are included in
Additional file 2.
Mitochondrial copy number
Measurement of mitochondrial (mt)DNA copy number
has been described previously [21]. Total DNA samples
were isolated using the QIAamp DNA Blood Mini Kit,
following the manufacturer’s protocol (Sigma-Aldrich).
Relative copy numbers of the single-copy nuclear-encoded
gene beta-2-microglobulin (β2M) and the mitochondrially
encoded gene mtND1 were measured by quantitative
(Q)-PCR using SYBR Green Mastermix (Eurogentec Ltd.)
and the DNA Engine Opticon 2 system (BioRad). The
Q-PCR primer sequences are in Additional file 2. To de-
termine the mtDNA content, relative to nuclear DNA, the
following equations were used:
a. ΔCT = (nucDNA CT −mtDNA CT)
b. Relative mtDNA content = 2 × 2ΔCT
Respirometry
Oxygen consumption rates (OCR) and extracellular acid-
ification rates (ECAR) were determined using a Seahorse
XF96 Analyser (Seahorse Bioscience). Respiratory profiles
were generated by serial treatment with optimised con-
centrations of oligomycin (1 μg/mL), p-[trifluoromethox-
y]-phenyl-hydrazone (FCCP, 500 nM) and rotenone (500
nM). Glycolytic profiles were generated by serial treat-
ment of glucose-restricted cells with optimised concentra-
tions of glucose (12.5mM), oligomycin A (1 μM), and
2-DG (50mM). Cell number normalisation was carried
out post-respirometry using sulforhodamine B (SRB)
staining of TCA-fixed cells in the assay plate.Mitochondrial fractionation
Crude mitochondrial fractions were prepared from cul-
tured cells as follows. All tubes and reagents were
pre-chilled, and all steps carried out at 4 °C or on ice.
Cells were collected and washed twice with homogenisa-
tion buffer (HB) (250 mM Mannitol, 5 mM HEPES (pH
7.4), 0.5 mM EGTA, in water). Pellets were resuspended
in 1 mL of HB and transferred to a chilled glass potter.
Cells were lysed with 150 strokes of potter on ice, and
50 μL of homogenate removed for whole cell lysate
(WCL) sample. The remaining lysate was spun at
1000xg for 5 min at 4 °C. Supernatants were transferred
to fresh tubes and spun at 2000xg for 5 min at 4 °C. Su-
pernatants were again transferred to fresh tubes and
spun at 10,000xg for 10 min at 4 °C. Fifty microlitres of
supernatants were retained as the cytoplasm sample.
Mitochondrial pellets were washed with 2–3 mL HB and
spun at 10,000xg for 10 min at 4 °C. Supernatants were
carefully removed, and mitochondrial pellets were resus-
pended in 200 μL HB for functional assays or 200 μL 1×
Laemmli sample buffer for immunoblotting. The func-
tionality of isolated mitochondria was monitored using
TMRM staining, which measures mitochondrial mem-
brane potential (Additional file 3f ).
SILAC
Cells were incubated in arginine and lysine free DMEM
(#A14431, Life Technologies), supplemented with either
(light) L-lysine (#L8662) and L-arginine (#A5006), or
(heavy) L-lysine-13C6,
15N2 (Lys-8, #608041)) and L-argi-
nine-13C6,
15N4 (Arg-10, #608033) stable isotope-labelled
amino acids (Sigma-Aldrich). Media was also supple-
mented with 10% dialysed FCS (Sigma), penicillin (100
IU/mL), streptomycin (100 μg/mL) and L-glutamine
(200 mM), all purchased from Life Technologies. Amino
acid incorporation was carried out over > 5 passages.
Mitochondrial fractions were isolated as described
below. Fifty micrograms of enriched mitochondria were
resolved approximately 6 cm into a pre-cast 4–12%
Bis-Tris polyacrylamide gel (ThermoFisher Scientific).
The lane was excised and cut in 8 approximately equal
chunks, and the proteins reduced, alkylated and digested
in-gel. The resulting tryptic peptides were analysed by
LC-MSMS using a Q Exactive coupled to an
RSLCnano3000 (ThermoFisher Scientific). Raw files
were processed using MaxQuant 1.5.2.8 using Androm-
eda to search a human Uniprot database (downloaded
03/12/14). Acetyl (protein N-terminus), oxidation (M)
and deamidation (N/Q) were set as variable modifica-
tions and carbamidomethyl (C) as a fixed modification.
SILAC data was loaded in R to process it with the
microarray-oriented limma package to call for differen-
tial expression [22], relying on the original normalisation
processes produced by MaxQuant as reported previously
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control U2OS and CHCHD4 (WT.cl1)-expressing cells
involving parallel labelling were performed. Two inde-
pendent SILAC experiments using shRNA control and
CHCHD4 (shRNA) knockdown cells involving parallel
labelling were performed.
Sulforhodamine B (SRB) assay
Cells were plated in appropriate tissue culture vessels
and allowed to adhere overnight prior to treatment.
Media was removed and cells were fixed with 10%
trichloroacetic acid (TCA, #91228, Sigma-Aldrich) for
30 min. TCA was washed with water, wells were allowed
to air dry and then an excess of 0.4% (w/v) SRB (#S9012,
Sigma-Aldrich) in 1% acetic acid (A/0400/PB15, Ther-
moFisher Scientific) was used to stain fixed cells for >
10min. Excess SRB was washed off with 1% acetic acid
solution. Bound SRB was resuspended in a suitable vol-
ume of 10 mM Tris, and absorbance of solution mea-
sured at 570 nm. For proliferation assays, cells were
plated on ‘day -1’ in triplicate in 12 well plates and cul-
tured in maintenance DMEM overnight, after which ‘day
0’ plates fixed with TCA. For galactose conditions, glu-
cose media were replaced with glucose-free DMEM,
supplemented with 4.5 g/L galactose, 10% FCS, penicil-
lin, streptomycin and L-glutamine, and 1mM pyruvate.
Cells were then incubated for desired time points in ei-
ther normoxia or hypoxia, followed by SRB assay. For
drug sensitivity assays, cells were plated in triplicate col-
umns in 96-well plates and cultured in maintenance
DMEM overnight. Appropriate wells were dosed with
serial dilutions of compounds, including vehicle control
wells. Cells were incubated for desired time points in ei-
ther normoxia or hypoxia, followed by SRB assay. SRB
data were used to calculate relative growth as indicated
in the relevant figure legend text and were consistent
with independent total cell count (data not shown). To
evaluate changes in drug sensitivity between cell lines,
we calculated the concentration at which growth was
inhibited by 50% (IC50) for each drug per cell line. To
account for any changes in growth rate between cell
lines, we also calculated the concentration for growth
rate inhibition (GR) at 50% (GR50) of the concentration
at which maximum growth is inhibited (GRmax) in the
presence of drug relative to the untreated control as pre-
viously described [25].
CI assay
For evaluating the direct inhibitory effect of compounds
on CI activity from whole CI enzyme immunocaptured
from purified bovine heart mitochondria, the MitoTox™
Complex I OXPHOS Activity Microplate Assay (Abcam,
ab109903) was used according to the manufacturer’s in-
structions. The IC50 was determined by calculating thedose at which CI activity was inhibited by 50%. This was
calculated as 5–50 nM for rotenone and 50–500 nM for
BAY 87-2243 (see Fig. 4a).
ATP assay
Cellular ATP concentrations were determined using
CellTiter-Glo Luminescent Cell Viability Assay reagent
and protocol, purchased from Promega (G7570). Briefly,
cells were incubated in parallel in appropriate culture
vessels under the conditions and for the duration of time
described in the figure legends. Cells were lysed by the
addition of a volume of CellTiter-Glo reagent equal to
the volume of the culture media and incubated for 2 min
on an orbital shaker at room temperature. One hundred
microlitres of each sample was loaded into a 96-well
luminometry plate, and the luminescence of each sample
was measured using a Tecan Infinite M200 PRO lumi-
nescent plate reader. Parallel cell incubations were
assayed for total cell content using the SRB assay, and
the luminescence measurements were normalised to the
respective SRB measurements.
Live cell imaging
Cells were plated in glass-based black-walled multi-
welled microscopy plates and allowed to adhere over-
night. Following treatments (as described in figure
legends), the plates were sealed with air-tight adhesive
film and imaged on a heated stage, using a DMI4000 B
inverted microscope (Leica).
Flow cytometry
For TMRM staining, mitochondria were harvested ac-
cording to protocol detailed here, resuspended in
DMEM supplemented with 1 mM L-pyruvate and 200
nM TMRM and incubated for 30 min at 37 °C and 5%
CO2. After staining, mitochondria were washed twice in
PBS, before resuspension in PBS, followed by flow cyto-
metric analysis using a Fortessa flow cytometer (BD Bio-
sciences). For MitoView staining, cells were harvested by
trypsinisation, and centrifugation, and washed twice in
warmed PBS. Cells resuspended in warmed PBS, or
warmed PBS containing 200 nM MitoView (green).
Fluorescence intensity was measured using a FACSCali-
bur flow cytometer (BD Biosciences). For 2-NBDG up-
take assay, cells in suspension were incubated in
warmed (37 °C) PBS or warmed PBS containing 200 μM
2-NBDG for 20 min. Cells were then washed three times
in warmed PBS followed by flow cytometric analysis
using a Fortessa flow cytometer (BD Biosciences).
Quantification of microscopy images
For MitoSOX staining, images were processed using Cell
Profiler Image analysis software, and fluorescence inten-
sity was calculated per field of view. Mean fluorescence
Thomas et al. Cancer & Metabolism             (2019) 7:2 Page 5 of 18intensity, standard error and significance were calculated
for each condition.
Quantification of western blots (densitometry)
Western blot signal intensity was measured per lane
using ImageJ (NIH) analysis software. Sample protein
band intensities were normalised to the load control
protein α-tubulin (for whole cell lysates) or PHB1 (for
mitochondrial fractions). Relative band intensities were
calculated relative to internal control sample.
Statistical analysis
All statistical analyses carried out using Microsoft Excel
(2016 edition) or GraphPad Prism version 7.02 for
Windows. Groups compared using unpaired, two-tailed
student’s t test assuming equal variance, with signifi-
cance set at p < 0.05. All error bars represent standard
deviation from the mean (SD) except where stated.
Sample numbers (n values) and significance marks indi-
cated in figure legends. Area under the curve was cal-
culated for each condition or cell line, and significance
of difference between groups calculated using student’s
t test.
Results
Impact of CHCHD4 on the mitochondrial proteome
CHCHD4 is responsible for the binding and import of
mitochondrial proteins containing a twin CX9C or CX3C
motif including subunits of respiratory chain complexes
[8, 10]. Previously, we demonstrated that CHCHD4 is
required for maintaining basal cellular (OCR) [3] and
intracellular oxygenation in tumour cells [4]. Recently,
we found that loss of CHCHD4 in renal carcinoma cells
leads to decreased expression of a range of respiratory
chain subunits including NDUFS3 (CI), SDHA (complex
II, CII), UQCRC2 (complex III, CIII) and COXIV (CIV)
[26], indicating that CHCHD4 controls the expression of
a broader range of respiratory chain subunits than had
previously been considered. Thus, we hypothesised that
CHCHD4 affects basal cellular OCR and intracellular
oxygenation by altering the expression levels of respira-
tory chain subunits. To investigate the extent to which
CHCHD4 affects respiratory chain subunit expression
and other mitochondrial proteins, we performed stable
isotope labelling with amino acid in cell culture (SILAC)
using L-lysine-13C6,
15N2 (Lys-8) and L-arginine-
13C6,
15N4 (Arg-10) parallel double labelling of shRNA control
and CHCHD4 (shRNA) knockdown cells, as well as
CHCHD4 (WT)-expressing cells and control cells
(Fig. 1a). Mitochondria were isolated and mass spectro-
photometry performed. Approximately 1050–1450 pro-
teins were analysed from up to three independent
parallel double labelling SILAC experiments (Fig. 1b, c).
Our analysis of proteins isolated from mitochondria ofrespectively labelled cells confirmed a significant de-
crease in CHCHD4 protein in CHCHD4 (shRNA)
knockdown compared to shRNA control cells (Fig. 1b)
and a significant increase in CHCHD4 protein in
CHCHD4 (WT)-expressing cells compared to control
cells (Fig. 1c). We observed respective decreased and in-
creased expression of several known CHCHD4 sub-
strates containing a twin-CXnC motif including COX17,
COA6, TIMM8, CHCHD2 and TIMM13 [8, 27] as well
as other putative CHCHD4 substrates (Fig. 1d and
Table 1), while expression of proteins such as the outer
mitochondrial membrane protein sorting and assembly
machinery component 50 homologue (SAMM50) did
not change. Most interestingly, we observed significant
and dynamic changes in a broad range of respiratory
chain subunits involving CI, CII, CIII and CIV
(Fig. 1e–g, Additional file 3 and Table 1). Notably, we
observed more significant protein changes in response
to loss of CHCHD4 (Fig. 1b, Table 1) compared to
CHCHD4 overexpression (Fig. 1c, Table 1), which was
likely related to the respective differences in significance
for CHCHD4 expression in each of these conditions
(Table 1). Importantly, we consistently observed that fold
changes of identified proteins in response to loss or gain
of CHCHD4 expression were decreased and increased
respectively across multiple SILAC experiments (Fig. 1
and Table 1).
To confirm our SILAC findings, we examined the ex-
pression of individual subunits of CI, CII, CIII and CIV
in whole cell and enriched mitochondrial fractions by
western analyses. Consistent with our SILAC analyses,
we found reduced expression of individual subunits of
CI (NDUFS3), CII (SDHA), CIII (UQCRC2) and CIV
(COXIV) in enriched mitochondrial fractions isolated
from stable CHCHD4 (shRNA) knockdown cells com-
pared to shRNA control cells (Fig. 1f ). Depletion of
CHCHD4 using two independent siRNAs similarly re-
duced the expression of these respiratory chain subunits
(Additional file 3b), as we have also shown in our recent
study using renal carcinoma cells [26]. Furthermore,
consistent with a previous report [28], we found that loss
of CHCHD4 also reduced the expression of AIF protein,
as well as GFER (Additional file 3c) without affecting
their respective mRNA expression (Additional file 3d).
Conversely, we found elevated levels of subunits of CI
(NDUFS3), CII (SDHA), CIII (UQCRC2) and CIV
(COXIV) in whole cell lysates and in enriched mito-
chondrial fractions isolated from CHCHD4 (WT)-ex-
pressing cells compared to control cells Fig. 1g.
However, these respiratory chain subunits were not in-
creased in cells expressing a mutant form of CHCHD4
(C66A/C68A) in which the functionally critical cysteines
of the substrate-binding CPC motif have been
substituted by alanine and is defective in mitochondrial
a b
f g h
e
i
d c
j k
Fig. 1 (See legend on next page.)
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Fig. 1 Impact of CHCHD4 on the mitochondrial proteome. a Schematic of SILAC procedure. HCT116 cells expressing control (non-targeting)
shRNA or expressing CHCHD4-targeting shRNA and control U2OS or CHCHD4 (WT)-expressing U2OS cells (WT.cl1) cells were incubated in either
L-lysine and L-arginine (light) or L-lysine-13C6,
15N2 (Lys-8) and L-arginine-
13C6,
15N4 (Arg-10) (heavy)-containing media for at least 5 cell divisions.
Mitochondrial fractions were prepared, and sample pairs were combined prior to LC-MS analysis. b Volcano plot showing log2 expression ratios
of all detected proteins (1050) in enriched mitochondrial fractions from U2OS cells expressing CHCHD4-targeting shRNA compared to control
(non-targeting) shRNA expressing cells n = 2 independent SILAC experiments each involving parallel double labelling of cells. c Volcano plot
showing log2 expression ratios of all detected proteins (1450) in enriched mitochondrial fractions from CHCHD4 (WT.cl1) expressing U2OS cells
compared to control U2OS cells. CHCHD4 highlighted (red dot) n = 3 independent SILAC experiments each involving parallel double labelling of
cells. d Volcano plot showing log2 expression ratios of known CHCHD4 substrates containing a twin-CxnC motif identified from our SILAC
analyses described in a. SAMM50 is highlighted (yellow) as a mitochondrial protein that does not significantly change and is not a predicted
CHCHD4 substrate. Dashed line denotes significance threshold, calculated by Student’s t test, expressed as -log10 of calculated p value. e Volcano
plots, showing changes in respiratory chain CI (left) and CIV (right) protein subunits from our SILAC analyses described in a and c. Log2
expression ratios in WT.cl1 vs control U2OS (blue circles) and CHCHD4 shRNA1 vs control shRNA (red circles) are shown. f Western blots show
NDUFS3, SDHA, UQCRC2, COXIV and CHCHD4 protein levels in whole cell lysates (WCL) and mitochondrial fractions (mitochondria) prepared from
control HCT116 (NT) and HCT116 cells stably expressing an shRNA control vector (shRNA Ctrl1) or shRNA(1) targeting CHCHD4 (CH shRNA). PHB1
was used as a mitochondrial load control, and α-tubulin was used as total load control. Densitometric ratio of each mitochondrial protein relative
to PHB1 load is indicated, n = 3. g Western blots show NDUFS3, SDHA, UQCRC2, COXIV and CHCHD4 protein levels in whole cell lysates (WCL)
and mitochondrial fractions (mitochondria) prepared from control U2OS (Ctrl), CHCHD4 (WT)-expressing (WT.cl1, WT.cl3) and CHCHD4 (C66A/
C68A)-expressing cells. PHB1 was used as a mitochondrial load control and α-tubulin was used as total load control. Densitometric ratio of each
mitochondrial protein relative to PHB1 load is indicated. n = 3. h, i Graphs show mtDNA copy number calculated as ratio of mt-ND1 and B2M
expression analysed by Q-PCR using total DNA isolated from cells described in f and g, respectively. n = 3. mean ± SD, n.s. not significant. j Graph
shows basal OCR (pmol/min) measured in cells described in f. n = 3. mean ± SD, ***p < 0.001. k Graph shows basal and maximal OCR (pmol/min)
measured in cells described in (g). n = 3. mean ± SD, n.s. not significant, ***p < 0.001
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noted that stable expression of the CHCHD4 (C66A/
C68A) mutant protein compared to CHCHD4 (WT) pro-
tein was much reduced in respective independent cell
lines (Fig. 1g). Despite this, we found that respiratory
chain subunit expression in CHCHD4 (C66A/C68A)-ex-
pressing cells were in some instances below basal levels
found in control cells (see Fig. 1g, WCL for NDUFS3 and
SDHA proteins). These data collectively indicate that the
mutant form of CHCHD4 (C66A/C68A) may behave as a
dominant negative, and as such, high levels of CHCHD4
(C66A/C68A) expression in cells might not be tolerated.
Interestingly, we observed no significant change in mito-
chondrial mass when CHCHD4 expression was manipu-
lated as assessed either by measuring mitochondrial
(mt)DNA copy number (Fig. 1h, i) or by staining with the
fluorescent mitochondrial marker, MitoView (Add-
itional file 3e). Moreover, mitochondrial membrane poten-
tial was similar in mitochondria isolated from CHCHD4
(WT)-expressing cells, CHCHD4 (C66A/C68A)-expres-
sing cells and control cells (Additional file 3f). Expression
of the inner membrane protein prohibitin 1 (PHB1) served
as a control protein for these experiments as it did not
change in response to either CHCHD4 (WT or C66A/
C68A) expression or CHCHD4 knockdown (Fig. 1f, g).
Previously, we showed that transient siRNA knockdown
and overexpression of CHCHD4 decreased and increased
basal cellular OCR, respectively [3]. Consistently, we
found that stable shRNA knockdown of CHCHD4 led to a
significant decrease in cellular OCR (Fig. 1j). Furthermore,
we found that both basal and maximal cellular OCRs were
significantly increased in CHCHD4 (WT)-expressing cells,but not in mutant CHCHD4 (C66A/C68A)-expressing
cells (Fig. 1k). Collectively, our data indicate that modula-
tion of CHCHD4 expression leads to global and dynamic
effects on the expression of mitochondrial respiratory
chain subunits and concomitant changes in basal OCR.
CHCHD4 promotes basal and adaptive metabolic
responses and provides a proliferative advantage to
tumour cells
We have previously reported that overexpression of
CHCHD4 in human cancers correlates with a hypoxia
gene signature and increased tumour progression and me-
tastasis, disease recurrence and poor patient survival [3].
As our SILAC analyses demonstrated significant changes
in the expression of respiratory chain subunits, next we
assessed the effect of CHCHD4 expression on tumour cell
metabolism and growth in normoxia and hypoxia. In nor-
moxia, we observed significantly decreased L-lactate levels
(Fig. 2a) and extracellular acidification rate (ECAR)
(Fig. 2b) in CHCHD4 (WT)-expressing cells compared
with control or CHCHD4 (C66A/C68A)-expressing cells.
Moreover, the rate of uptake of the fluorescent glucose
analogue 2-NBDG (2-(N-(7-nitrobenz-2-oxa-1,3-diazo-
l-4-yl)amino)-2-deoxyglucose) was slower in CHCHD4
(WT)-expressing cells compared with control U2OS cells,
while CHCHD4 (C66A/C68A)-expressing cells had higher
uptake (Fig. 2c). Together, these data indicate that in-
creased respiratory chain subunit expression correlates
with decreased glycolysis in response to elevated
CHCHD4 expression in normoxia, and decreased fermen-
tation of pyruvate to lactate. In contrast to our findings in
normoxia, we observed significantly increased L-lactate
Table 1 Twin-CXnC motif-containing proteins identified in CHCHD4 (shRNA) knockdown cells and CHCHD4 (WT)-expressing cells
using SILAC analysis
Protein Accession
(HGNC)
CXC motifs Function Mean fold change
CH shRNA/shRNACtrl WT.cl1/control
Coiled-coil-helix-coiled-coil-helix
domain-containing 4; CHCHD4
26467 CX9C, CX9C [3] Mitochondrial import [53] 0.62 (****) 4.48 (*)
Coiled-coil-helix-coiled-coil-helix
domain-containing 1; CHCHD1
23518 CX9C, CX9C [38] Mitochondrial ribosome [38] 0.86 (***) 1.03
Coiled-coil-helix-coiled-coil-helix
domain-containing 2; CHCHD2§
21645 CX9C, CX9C [54] CIV activity/assembly [8, 54] n.d. 0.63
Coiled-coil-helix-coiled-coil-helix
domain-containing 4; CHCHD6§
28184 CX9C, CX9C [55] Cristae morphology [56] 0.86 1.06
NADH:ubiquinone oxidoreductase
subunit A8; NDUFA8§
7692 CX9C, CX9C [40] CI activity/assembly [8] 0.79 (****) 1.17
NADH:ubiquinone oxidoreductase
subunit B7; NDUFB7§
7702 CX9C, CX9C [40] CI activity/assembly [8] 0.82 (**) 1.12 (*)
NADH:ubiquinone oxidoreductase
subunit B10; NDUFB10§
7696 CX6C, CX11C [57] CI activity/assembly [8, 57] 0.86 (**) 1.13
NADH:ubiquinone oxidoreductase
subunit S5; NDUFS5§
7712 CX9C, CX9C [40] CI activity/assembly [8] 0.81 (***) 1.11
Ubiquinol-cytochrome c reductase
hinge protein; UQCRH
12590 CX10C, CX9C [58] CIII assembly/activity [59] 0.96 1.05
C-X9-C motif-containing 1; CMC1 28783 CX9C, CX9C [60] CIV assembly/activity [61] 0.68 (****) 1.10
Cytochrome c oxidase assembly
factor 6; COA6§
18025 CX9C, CX10C [62] CIV assembly/activity [63] 0.70 (****) 2.00 (*)
Cytochrome c oxidase subunit 6B1;
COX6B1
2280 CX9C, CX10C [64] CIV assembly/activity [8, 64] 0.81 (**) 1.43 (**)
Cytochrome c oxidase copper
chaperone; COX17
2264 CX9C, CX9C [53] CIV assembly/activity [65] n.d. 2.34 (*)
Translocase of inner mitochondrial
membrane 8 homologue A; TIMM8A§
11817 CX3C, CX3C [66] Matrix protein import [8, 67] 0.71 (*) 1.30 (*)
Translocase of inner mitochondrial
membrane 8 homologue B; TIMM8B§
11818 CX3C, CX3C [66] Matrix protein import [67] 0.76 (*) n.d.
Translocase of inner mitochondrial
membrane 9; TIMM9
11819 CX3C, CX3C [66] Matrix protein import [67] 0.80 (***) 1.40 (***)
Translocase of inner mitochondrial
membrane 10; TIMM10§
11814 CX3C, CX3C [66] Matrix protein import [8, 67] n.d. 1.07
Translocase of inner mitochondrial
membrane 10B; TIMM10B§
4022 CX3C, CX3C [66] Matrix protein import [67] 0.81 (*) 1.08
Translocase of inner mitochondrial
membrane 13; TIMM13§
11816 CX3C, CX3C [66] Matrix protein import [8, 67] 0.77 (*) 1.47 (*)
Table shows selected proteins, their respective twin-CXnC motif and the fold change in their mitochondrial availability in CHCHD4 (shRNA) knockdown cells
compared to control shRNA cells and CHCHD4 (WT)-expressing compared to control cells. Known CHCHD4-binding proteins are indicated (§). Representative
mean fold changes in proteins observed in response to CHCHD4 knockdown were calculated from two parallel labelling analyses (CHCHD4 shRNA(H) vs shRNA
Ctrl(L) and CHCHD4 shRNA(L) vs shRNA Ctrl(H)) from two independent SILAC experiments. Representative mean fold changes in proteins observed in response to
elevated CHCHD4 expression were calculated from two parallel labelling analyses (WT(H) vs Ctrl(L) and WT(L) vs Ctrl(H)) from three independent SILAC
experiments for all proteins shown, except CHCHD2 and TIMM8A where data was from two independent SILAC experiments.
Proteins significantly changed are indicated *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Proteins not detected or showing no reproducible change between
experiments are indicated (n.d.)
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pared with control or CHCHD4 (C66A/C68A)-expressing
cells (Additional file 4a), as we have shown previously [3].
Alongside this, we observed a corresponding change in
the expression of the hypoxia inducible factor (HIF) target
lactate dehydrogenase A (LDHA) (Additional file 4b),
which converts pyruvate to lactate. Furthermore, we foundthat elevated CHCHD4 expression led to significantly in-
creased tumour cell growth in both normoxia (Fig. 2d)
and hypoxia (Additional file 4c), while the growth of
CHCHD4 (C66A/C68A)-expressing cells was similar to
control cells (Fig. 2d and Additional file 4c), indicating
that increased expression of CHCHD4 in tumour cells
provides a proliferative advantage in both normoxia and
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CHCHD4-mediated effects on the respiratory chain regu-
late both basal (normoxic) and adaptive (hypoxic) meta-
bolic tumour cell responses and growth.
CHCHD4 expression confers increased tumour cell
sensitivity to CI inhibitors
Homozygous deletion of chchd4 in mice, which is em-
bryonic lethal, results in a decrease in whole CI expres-
sion [28], and human CI deficiency which is fatal is
associated with a cysteine mutation within the CI
accessory subunit NDUFB10, which is a CHCHD4 sub-
strate [29]. Our SILAC analyses of CHCHD4 (shRNA)
knockdown and shRNA control cells showed a decrease
in the expression of a range of CI accessory subunits
(Fig. 1e, red dots). Conversely, CHCHD4 (WT)-expres-
sing cells compared to control cells showed an increase
in the expression of a range of CI subunits including
NDUFS3, as well as NDUFA8, NDUFB10 and NDUFB7,
which are considered to be CHCHD4 substrates [8, 27]
(Fig. 1e, blue dots and Additional file 5). Given this rela-
tionship between CHCHD4 and CI biology, we hypothe-
sised that elevated expression of CHCHD4 in tumour
cells may render them more sensitive to respiratory
chain OXPHOS inhibitors. Indeed, we found that
CHCHD4 (WT)-expressing cells were significantly more
sensitive to growth inhibition by the CI inhibitor rote-
none (IC50 20-40 nM, GR50 40-60 nM) compared to con-
trol or mutant CHCHD4 (C66A/C68A)-expressing cells
(IC50 150-300 nM) in normoxia (Fig. 3a) and hypoxia
(Additional file 6a), while there was no significant differ-
ence in the effects of sodium azide on growth across cell
lines (Fig. 3b and Additional file 6b). As with sodium
azide (Additional file 6c), rotenone also blocked HIF-1α
protein (Additional file 6d). Together, our data show that
the increased sensitivity of CHCHD4 (WT)-expressing
cells to growth inhibition is specific to CI inhibition
(rotenone) as opposed to CIV inhibition (sodium azide)
and occurs irrespective of oxygen levels.
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Fig. 3 CHCHD4 expression confers increased tumour cell sensitivity to CI inhibitors. a Graph shows relative growth of control U2OS (control) cells,
two independent CHCHD4 (WT)-expressing cell clones (WT.cl1, WT.cl3) and CHCHD4 (C66A/C68A)-expressing cells incubated for 72 h in the absence
or presence of rotenone using a 2-fold dilution series (top concentration, 1 μM). Data are presented for each time point for rotenone-treated relative
to untreated. n = 3, mean ± SD, *p < 0.05. b As in a, using a 10-fold dilution series of sodium azide (top concentration, 100 μM). n = 3, mean ± SD. c
Images of control U2OS cells, CHCHD4 (WT)-expressing cells (WT.cl1, WT.cl3) and CHCHD4 (C66A/C68A)-expressing cells, either untreated (NT) or
treated with rotenone (500 nM) for 3 h. MitoSOX Red ROS indicator (5 μM) was added for 30min prior to live cell imaging by fluorescence microscopy.
d Graph shows the percentage of the mean fluorescence intensity quantified from images of cells described in c. n = 5 images per condition, mean ±
SD, n.s. not significant, *p < 0.05, **p < 0.01. e Images of cells described in c, either untreated (NT) or treated with sodium azide (NaAzide, 5 mM) for 3 h.
MitoSOX Red ROS indicator (5 μM) was added for 30min prior to live cell imaging by fluorescence microscopy
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which can have profound effects on cellular viability
through oxidative damage to lipids, proteins and nucleic
acids [30]. Therefore next, we assessed mitochondrial
ROS (superoxide) production using the ROS reporter
MitoSOX. We found that basal ROS levels were similarly
low in control and CHCHD4 (WT)-expressing cells
(Fig. 3c–e). However, in response to rotenone, ROS
levels were significantly increased in CHCHD4 (WT)-ex-
pressing cells compared to control or CHCHD4 (C66A/
C68A)-expressing cells (Fig. 3c, d). Treatment of cells
with sodium azide did not lead to a change in mitochon-
drial ROS levels (Fig. 3e). Thus, the increased sensitivity
of CHCHD4 (WT)-expressing cells to CI inhibitors
(rotenone) correlates with increased ROS production in
these cells, suggesting that CHCHD4 expression levels
determines tumour cell sensitivity to oxidative stress.
CHCHD4 promotes mitochondrial ROS production in
response to CI inhibitors
To further explore the relationship between CHCHD4
and CI biology, we evaluated the effects of CI inhibition
in CHCHD4 (WT)-expressing cells using the small mol-
ecule inhibitor BAY 87-2243 [31]. BAY 87-2243 was pre-
viously identified from a HIF-reporter screen and was
shown to block HIF-1α by targeting CI without inhibit-
ing CIII [31]. BAY 87-2243 exhibits potent antitumor ac-
tivity in vivo [31–33] and has recently been shown to
induce mitochondrial ROS through its CI inhibitory ac-
tivity [34]. The IC50 dose (~ 500 nM) of BAY 87-2243 for
inhibiting whole CI enzyme activity, which was 10–100
fold less potent than rotenone in this assay (Fig. 4a), also
blocked basal OCR by ~ 50% (Additional file 7a). Con-
sistent with our findings with rotenone (Fig. 3a), we
found that CHCHD4 (WT)-expressing cells were signifi-
cantly more sensitive to growth inhibition by BAY
87-2243 treatment compared to control or mutant
CHCHD4 (C66A/C68A)-expressing cells in normoxia
(Fig. 4b) and hypoxia (Additional file 7b). Notably, the
increased sensitivity of CHCHD4 (WT)-expressing cells
to BAY 87-2243 was observed at very low nM doses
(IC50 1–5 nM, GR50 1.5–4.5 nM) compared to control or
CHCHD4 (C66A/C68A)-expressing cells (IC50 10–100
nM) (Fig. 4b and Additional file 7b) in normoxia and
hypoxia. Interestingly, although we found that BAY
87-2243 blocked whole CI enzyme activity by 10–15% at
doses as low as 5 nM in vitro (Fig. 4a), there was no sig-
nificant change in basal cellular OCR (Additional file 7a)
or total cellular ATP levels (Additional file 7c) at a 5 nM
dose of BAY 87-2243 treatment, suggesting that the ef-
fect of CI inhibition on growth inhibition is not solely
mediated by changes at the level of intracellular oxygen-
ation or bioenergetics. Indeed, similar to our findings
with rotenone (Fig. 3c, d), ROS levels were significantlyincreased in CHCHD4 (WT)-expressing cells compared
to control and CHCHD4 (C66A/C68A)-expressing cells
in response to BAY 87-2243 treatment, even at a very
low dose of 5 nM (Fig. 4c, d). Addition of a ROS scaven-
ger to rotenone-treated cells has been shown to reduce
ROS production and rescue cell death [35]. Here, we
found that addition of the ROS scavenger Trolox signifi-
cantly reduced ROS levels induced by BAY 87-2243
(Fig. 4c, d) and rotenone (data not shown) and partially
rescued the growth inhibitory effect of BAY 87-2243
treatment in CHCHD4 (WT)-expressing cells (Fig. 4e).
To examine the growth inhibitory effects of BAY
87-2243 treatment in the context of CHCHD4 loss, we
used U2OS cells stably expressing either control shRNA
or CHCHD4 shRNA (Fig. 5). We found that CHCHD4
(shRNA) knockdown led to significantly reduced tumour
cell growth when cells were cultured in glucose-free
(galactose-containing) media (Fig. 5a) which forces them
to utilise the respiratory chain and produce ATP via
OXPHOS [36]. Importantly, we found that CHCHD4
(shRNA) knockdown cells were significantly less sensi-
tive to BAY 87-2243 treatment compared to control
shRNA cells (Fig. 5b). These data correlate with our
findings for CHCHD4 (WT)-expressing cells (Fig. 4e).
Collectively, our data indicate that CHCHD4 expression
confers increased tumour cell sensitivity to mitochon-
drial ROS produced by CI inhibitors.
CHCHD4-mediated HIF-1α induction is blocked by NSC-
134754 without affecting the respiratory chain
Previously, we have shown that CHCHD4 regulates
HIF-1α protein induction and HIF signalling in hypoxia
and is required for tumour growth in vivo [3]. Here, we
have found that elevated CHCHD4 expression increases
tumour cell growth rate (Fig. 2c and Additional file 4c)
and HIF-1α protein levels (Additional file 7c, d) in nor-
moxia and hypoxia. Thus, next we assessed the contri-
bution of HIF signalling to tumour cell growth rate
observed in response to elevated CHCHD4 without tar-
geting the respiratory chain. To do this, we used a small
molecule HIF pathway inhibitor that we previously identi-
fied, named NSC-134754 [16]. Additional file 8a shows
our revised chemical structure for NSC-134754 [20].
NSC-134754 blocks HIF activity in U2OS cells in nor-
moxia and hypoxia within the sub-μM range (IC50
0.25 ± 0.05 μM). NSC-134754 mediates no direct inhibi-
tory effects on basal OCR (Additional file 8b), does not in-
hibit whole CI enzyme activity (Fig. 6a) and does not
induce mitochondrial ROS (Fig. 6b), collectively indicating
that NSC-134754 blocks HIF signalling with no respira-
tory chain involvement. Moreover, in contrast to our
growth inhibitor data observed with CI inhibitors (Fig. 3a
and Fig. 4b), we found that NSC-134754 showed a com-
parable growth inhibitory profile (IC50 0.25–0.30 μM) in
Fig. 4 (See legend on next page.)
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Fig. 4 CHCHD4 promotes mitochondrial ROS production in response to CI inhibitors. a Graph shows dose-response curve of whole CI activity in
the presence of rotenone (black line) and BAY 87-2243 (blue line), using a 10-fold dilution series (top concentration 50 μM). b Graph shows relative
growth of control U2OS cells, CHCHD4 (WT)-expressing cells (WT.cl1, WT.cl3) and CHCHD4 (C66A/C68A)-expressing cells incubated for 72 h in the
absence or presence of BAY 87-2243 using a 2-fold dilution series (top concentration, 100 nM). Data are presented as BAY 87-2243-treated relative to
untreated (0 h). n = 3, mean ± SD. *p < 0.05. c Images of cells described in b, either untreated (NT) or treated with of BAY 87-2243 (5 nM) for 3 h, in the
absence (−) or presence (+) of the ROS scavenger Trolox (100 μM). MitoSOX Red ROS indicator (5 μM) was added for 30min prior to live cell imaging
by fluorescence microscopy. d Graph shows the percentage of the mean fluorescence intensity quantified from images of cells described in c, which
were either untreated (NT) or treated with BAY 87-2243 (5 nM), or with BAY 87-2243 (5 nM) and Trolox (100 μM) (BAY + Trolox) for 3 h. MitoSOX Red
ROS indicator (5 μM) was added for 30min prior to live cell imaging by fluorescence microscopy. n = 5 images per condition, mean ± SD, n.s. not
significant, *p < 0.05, **p < 0.01. e Graph shows the percentage of the growth of cells treated without (−) or with (+) BAY 87-2243 (5 nM) for 24 h, in
the absence (NT, black bars) or presence of Trolox (100 μM) (blue bars). Data are represented as the percentage of the growth of cells. n = 3, mean ±
SD. n.s. not significant, *p < 0.05, **p < 0.01
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moxia and hypoxia (Fig. 6c–e). Furthermore, we found
that elevated HIF-1α and HIF-2α protein induced in
CHCHD4 (WT)-expressing in normoxia and hypoxia was
blocked by NSC-134754 (Fig. 6f and Additional file 8c).
Collectively, our data show that our small molecule HIF
signalling inhibitor, NSC-134754, can significantly block
CHCHD4-mediated HIF-α protein induction without af-
fecting the respiratory chain, highlighting the potential for
targeting HIF signalling downstream of CHCHD4 and
out-with the mitochondrial respiratory chain (Fig. 7).
Discussion
Tumour cells rely on glycolysis and mitochondrial
OXPHOS to survive [1]. Thus, mitochondrial metabol-
ism has become an increasingly attractive area for inves-
tigation and therapeutic exploitation in cancer [2].
OXPHOS inhibitors are coming to the forefront for use
in specific cancer types [37]. However, given the import-
ance of mitochondrial OXPHOS for controlling intracel-
lular oxygenation required for normal physiological
processes, delineating whether or how OXPHOS inhibi-
tors might provide a therapeutic window in cancer is
crucially important.
Here, we provide evidence that CHCHD4 expression
in tumour cells is a critical determinant of the mito-
chondrial expression of a broad range of respiratory
chain subunits including individual subunits of CI, CII,
CIII and CIV, some of which are known CHCHD4
substrates (Table 1, Additional file 5 and [8]). These
CHCHD4-regulated proteins contain both canonical
(twin-CX9C or CX3C) and non-canonical (twin-CXnC)
cysteine motifs, suggesting that CHCHD4 is capable of
recognising and introducing disulfide bonds into pro-
teins with a more diverse arrangement of cysteines than
has previously been described [8]. In addition, we found
changes in the mitochondrial expression of proteins pre-
viously identified as Mia40 substrates in yeast (e.g.
CHCHD1 (Mrp10 in yeast) [38] (Table 1)).
Importantly, we found that increased expression of
CHCHD4 or CHCHD4 knockdown increases ordecreases respectively the expression of a number of
supernumerary CI subunits involved in CI assembly
(Table 1 and Additional file 5, [39]). Our data concur
with a previous study showing that targeted deletion of
chchd4 in mice results in embryonic lethality by day
E8.5, with null embryos displaying severe deficiency in
total CI expression, accompanied by less severe defects
in total CII-IV expression [28]. Interestingly, we identi-
fied at least four accessory CI subunits that are known
CHCHD4 substrates (NDUFA8, NDUFB7, NDUFS5 and
NDUFB10, Table 1). Three of these accessory CI sub-
units NDUFA8, NDUFB7 [40] and NDUFS5 [41] have
previously been identified as CHCHD4 substrates with
canonical twin CX9C motifs [8], while a fourth subunit
NDUFB10 contains a non-canonical cysteine motif
(CX6C-CX11C) (Table 1) and has been shown recently to
be mutated in a single case of fatal infantile lactic acid-
osis and cardiomyopathy in a way that renders it defect-
ive in binding to CHCHD4 [29]. A previous study
describing the systematic genetic deletion of each of the
31 CI accessory subunits in cells shows that loss of ei-
ther NDUFA8, NDUFB7, NDUFS5 or NDUFB10 has
detrimental effects on the expression of other CI sub-
units, indicating that each of these CI subunits are
strictly required for the assembly of whole CI [39]. Given
the role of CHCHD4 import within the IMS, it is par-
ticularly interesting that these four accessory subunits of
CI all reside within the IMS face of the CI structure [39,
42]. Therefore, it seems likely that CHCHD4 influences
whole CI assembly and activity primarily through its
ability to import multiple accessory CI subunits that are
integrally involved in CI assembly [39]. Indeed, of the 30
nuclear-encoded CI subunits identified in our SILAC
analyses (excluding those already confirmed as
CHCHD4 substrates), 16 have two or more cysteine resi-
dues that could potentially be recognised and oxidised
by CHCHD4 (Additional file 5). Intriguingly, we found
that mitochondrial expression of the core CI subunit
NDUFS3 [39] was also affected by modulation of
CHCHD4 expression (Fig. 1 and Additional file 5).
NDUFS3 knockdown has been shown to significantly
01
2
3
4
5
6
Glucose Galactose Glucose Galactose
Normoxia Hypoxia
)h0
sv
h27(
ht
wor
G
evitale
R
shRNA Control CHCHD4 shRNA1
n.s. n.s.
*
**
0
10
20
30
40
50
60
70
Control
shRNA
CHCHD4
shRNA
R
el
at
iv
e 
G
ro
w
th
 in
 G
lu
co
se
-f
re
e 
(G
al
ac
to
se
) 
(B
A
Y
 1
0 
nM
vs
 0
 n
M
)
Normoxia Hypoxia
**
***
*** ***
a
b
0
10
20
30
40
50
60
70
Control
shRNA
CHCHD4
shRNA
esocul
G
ni
ht
wor
G
evitale
R
(B
A
Y
 1
00
 n
M
vs
 0
 n
M
)
Normoxia Hypoxia
n.s.
**
n.s. ***
Fig. 5 CHCHD4 loss reduces tumour cell sensitivity to CI inhibitors. a Graph shows relative growth of U2OS cells stably expressing shRNA control
or CHCHD4 shRNA (CHCHD4 shRNA1) cultured in normoxia or hypoxia in either glucose or glucose-free (galactose) containing media for 72 h.
n = 3, mean ± SD, n.s. not significant, *p < 0.05, **p < 0.01. b Graphs show relative growth of cells described in a culture in normoxia and hypoxia
(1% O2) for 24 h in the absence and presence of BAY 87-2243 at the concentrations indicated, incubated in glucose or glucose-free (galactose)
containing media. Data are presented as BAY 87-2243-treated relative to untreated (0 nM). n = 2, mean ± SD, **p < 0.01, ***p < 0.001
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sion of NDUFS3 is associated with breast cancer inva-
siveness [44]. NDUFS3 is not a known or putative
CHCHD4 substrate (Additional file 5). However, re-
duced expression of NDUFS3 [45] and CI subunits as
well as other respiratory chain complex defects have
been observed upon loss or knockdown of
apoptosis-inducing factor (AIF) [28, 46]. CHCHD4 has
been shown to bind to AIF and is able to restore respira-
tory function in AIF-deficient cells [28]. Thus, CHCHD4
may also influence whole CI assembly and activity in
tumour cells via other proteins involved in DRS functionindependently of its ability to import CI accessory
subunits.
Collectively, our data highlight a fundamental relation-
ship between CHCHD4 function and CI biology. Target-
ing CI as a therapeutic strategy in cancer has recently
garnered considerable interest, due in part to the prom-
ising anticancer attributes of the antidiabetic drug met-
formin and the related biguanidine phenformin [1].
Metformin has been shown to block a variety of cellular
and metabolic processes including CI activity [47, 48].
However, targeting respiratory chain components as a
therapeutic strategy comes with considerable risk given
Fig. 6 (See legend on next page.)
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Fig. 6 CHCHD4-mediated HIF-1α induction is blocked by NSC-134754 without affecting the respiratory chain. a Graph shows dose-response
curve of whole CI activity in the presence of rotenone (black line) and NSC-134754 (green line), using a 10-fold dilution series (top concentration
50 μM). b Images of control U2OS cells, CHCHD4 (WT)-expressing cells (WT.cl1), either untreated (NT) or treated with NSC-134754 (1 μM) for 3 h.
MitoSOX Red ROS indicator (5 μM) was added for 30 min prior to live cell imaging by fluorescence microscopy. c, d Graphs show relative growth
of control U2OS (control) cells, two independent CHCHD4 (WT)-expressing cell clones (WT.cl1, WT.cl3) and CHCHD4 (C66A/C68A)-expressing cells
incubated for 72 h in the absence or presence of NSC-134754 using a 2-fold dilution series (top concentration, 1 μM), in either normoxia (c), or
hypoxia (1% O2) (d). Data are presented as NSC-134754-treated relative to untreated (0 h). e Graph shows relative growth of control U2OS
(control) cells and CHCHD4 (WT)-expressing cell clones (WT.cl1) for 72 h in the absence (−) or presence (+) of NSC-134754 (1 μM), in normoxia
(black bars) or hypoxia (1% O2, green bars). n = 3, mean ± SD, n.s. not significant, *p < 0.05, **p < 0.01. f Western blots show HIF-1α and
exogenous CHCHD4 (myc) protein from control U2OS and CHCHD4 (WT)-expressing cells (WT.cl1) incubated in normoxia or hypoxia (1%
O2) for 8 h in the absence (−) or presence (+) of NSC-134754 (1 μM). β-actin was used as load control
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cellular function. Tumour cells with elevated
CHCHD4 expression and increased CI subunit ex-
pression and activity produced significant levels of
mitochondrial ROS (superoxide) upon treatment with
CI inhibitors. However, elevated CHCHD4 expression
did not render tumour cells more sensitive to growth
inhibition by treatment with the CIV inhibitor sodium
azide.
CI and CIII are considered the major sites for mito-
chondrial ROS (superoxide) production [49]. While we
did not measure precisely where mitochondrial ROS
(superoxide) was being produced upon CI inhibition in
CHCHD4 (WT)-expressing cells, BAY 87-2243 has
been shown to block CI without inhibiting CIII [31]
and was recently shown to induce mitochondrial ROS
through its CI inhibitory activity [34]. Interestingly, a
recent study has implicated HIF-1 in the induction of
the CI subunit NDUFA4L2 as mechanism to prevent
overproduction of ROS during hypoxia [50]. However,
we found no change in NDUFA4L2 expression inFig. 7 Schematic demonstrating proposed model of separable regulation o
and CIV expression/activity, respectivelyresponse to increased (or decreased) CHCHD4 expres-
sion in our SILAC analyses.
Metabolic adaptation to hypoxia in tumours is primar-
ily mediated by HIFs and includes the diversion of
glucose-derived carbons from the TCA cycle and the
conversion of pyruvate to lactate, and by upregulation of
the enzymes pyruvate dehydrogenase kinase 1 (PDK1)
and LDHA [51, 52]. This reduces the reliance of cells on
mitochondrial OXPHOS for the production of ATP [52].
Indeed, here and previously, we have shown that ele-
vated expression of CHCHD4 in tumour cells increases
hypoxic production of cellular lactate [3]. Paradoxically,
here we found that elevated CHCHD4 expression in
tumour cells leads to significantly reduced levels of cel-
lular lactate in normoxia and no significant change in
PDK1 (data not shown), which is consistent with an in-
creased respiratory drive in these cells. It is highly pos-
sible that HIF transcriptionally dependent (negative)
regulatory effects on mitochondrial function are negated
in tumour cells expressing elevated CHCHD4 in
normoxia due to CHCHD4's increased drive off survival/proliferation and hypoxia responses by CHCHD4 through CI
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possibility that CHCHD4 expression confers a double
advantage to proliferating tumour cells by stimulating
more efficient glucose utilisation in both the presence
and absence of oxygen. Consistent with this idea, we
found that tumour cells with elevated CHCHD4 expres-
sion exhibit significantly increased proliferative capacity
in normoxia and hypoxia, suggesting that CHCHD4 is
capable of promoting tumour cell growth and metabolic
adaptive responses, potentially through increased re-
spiratory drive and HIF-mediated signalling respectively.
Indeed, we found that our small molecule inhibitor of
HIF signalling NSC-134754 [16, 18–20], which exhibits
anti-tumour activity in vivo [18, 53] could significantly
block tumour cell growth and HIF-α (HIF-1α and
HIF-2α) protein in tumour cells expressing elevated
CHCHD4, without mitochondrial respiratory chain
involvement.Conclusions
Mitochondria function as bioenergetic and biosynthetic
factories to support cell survival and proliferation and
are important regulators of intracellular oxygenation and
responses to hypoxia (reviewed [52]). Our present study
demonstrates that the mitochondrial protein CHCHD4
controls the mitochondrial expression of a broad range
of respiratory chain subunits. This reduces the glycolytic
demands of cultured tumour cells and provides a prolif-
erative advantage. However, our study also demonstrates
that elevated CHCHD4 expression renders tumour cells
more sensitive to growth inhibition by CI inhibitors, in
part by increasing ROS production. Furthermore, while
elevated CHCHD4 increases HIF-α protein induction in
hypoxia, this is also sensitive to respiratory chain inhib-
ition. Respiratory chain OXPHOS inhibitors may offer a
potential therapeutic route for the treatment of tumours
with increased proliferative drive, but this comes with a
significant risk of toxicity. Our study shows that our HIF
pathway inhibitor NSC-134754 potently inhibits the
growth of tumour cells with elevated CHCHD4 expres-
sion, without influencing mitochondrial function or ROS
production. Further exploration of the mechanism of ac-
tion of NSC-134754 will be particularly interesting.Additional files
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